FDA
-
-
-
-
-
-
-
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
-
-
-
-
-
-
-
NervGen Pharma to Participate at Upcoming Investor Conferences
-
-
-
-
-
-
-
NervGen Pharma Begins Trading on Nasdaq Today
-
-
-
-
-
-
324,023 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

